http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Clinical effects of belotecan in patients with recurrent ovarian, fallopian and peritoneal cancer
( Cheyon Park ),( Young Jin Lee ),( Eun Hyun Lee ),( Yong Il Ji ) 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Objective: The aim of this study is to evaluate the efficacy and safety of belotecan as second line chemotherapy in patients with recurrent ovarian, fallopian and peritoneal cancer. Methods: We identified patients who received second line chemotherapy for recurrent ovarian, fallopian and peritoneal cancer in Department of Obstetrics and Gynecology of Haeundae Paik Hospital from January 2010 to March 2020. Patients who were treated with belotecan as second line chemotherapy were classified into the experimental group (B) and patients who were treated with other chemotherapy agents were classified into the control group (O). We compared disease free survival, 5 year overall survival and toxic side effect between two groups. Results: A total of 78 patients received second line chemotherapy for recurrent ovarian cancer. 15 patients were B group and 63 patients were O group. The overall response of the patients was 40% (6/15) in B group and 31.7% (20/63) in O group. Median time to progression was 8.2 months in B group. Grade 3 and 4 toxicity was lower in group B than in group O. Conclusion: The efficacy of second line chemotherapy with belotecan in recurrent ovarian cancer patients was similar to that of other chemotherapy agents. In terms of toxicity, B group patients showed statistically lower incidence than O group patients. Based on the results of this study, belotecan may be a reasonable option for patients with recurrent ovarian, fallopian and peritoneal cancer.